 HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 GLOBE NEWSWIRE -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical RD in China, and Nabriva Therapeutics NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced positive topline results from Sinovants Phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia CABP. 